(S)-2-({(4R,5R)-5-[(benzo[1,3]dioxol-5-ylmethyl)carbamoyl]-[1,3]dioxolane-4-carbonyl}amino)-3-[4-(2,6-dichlorobenzyloxy)phenyl]-propionic acid | 848210-91-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-({(4R,5R)-5-[(benzo[1,3]dioxol-5-ylmethyl)carbamoyl]-[1,3]dioxolane-4-carbonyl}amino)-3-[4-(2,6-dichlorobenzyloxy)phenyl]-propionic acid
• 英文别名: (S)-2-((4R,5R)-5-(benzo[d][1,3]dioxol-5-ylmethylcarbamoyl)-1,3-dioxolane-4-carboxamido)-3-(4-(2,6-dichlorobenzyloxy)phenyl)propanoic acid；(2S)-2-[[(4R,5R)-5-(1,3-benzodioxol-5-ylmethylcarbamoyl)-1,3-dioxolane-4-carbonyl]amino]-3-[4-[(2,6-dichlorophenyl)methoxy]phenyl]propanoic acid
• CAS: 848210-91-3
• 化学式: C₂₉H₂₆Cl₂N₂O₉
• 分子量: 617.439
• InChiKey: JTASSQLBLFQSDP-HDYLNDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (S)-2-({(4R,5R)-5-[(benzo[1,3]dioxol-5-ylmethyl)carbamoyl]-[1,3]dioxolane-4-carbonyl}amino)-3-[4-(2,6-dichlorobenzyloxy)phenyl]-propionic acid
  参考文献：
  名称：

  Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists

  摘要：

  A novel set of compounds with a 1,3-dioxolane ring which acts as a proline bioisostere have been successfully designed as VLA-4 receptor antagonists. Compounds (18e), (28j), and (35g) were shown to have high receptor affinities. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.069

文献信息

• [EN] DIOXOLANE DERIVATIVES AS CELL ADHESION INHIBITORS<br/>[FR] DERIVES DE DIOXOLANE COMME INHIBITEURS DE L'ADHESION CELLULAIRE
  申请人：RANBAXY LAB LTD

  公开号：WO2005026163A1

  公开（公告）日：2005-03-24

  The present invention relates to dioxolane derivatives as cell adhesion inhibitors. These compounds can be useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. This invention also relates to pharmacological compositions containing the compounds of the present invention, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds.

  本发明涉及二氧杂环戊烷衍生物作为细胞粘附抑制剂。这些化合物可用于抑制和预防细胞粘附和细胞粘附介导的病理，包括诸如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥反应或银屑病等炎症性和自身免疫性疾病。本发明还涉及包含本发明化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥反应以及其他炎症性和/或自身免疫失调的方法。
• DIOXOLANE DERIVATIVES AS CELL ADHESION INHIBITORS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1668007A1

  公开（公告）日：2006-06-14
• Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists
  作者：Abdul Rehman、Ajay Soni、Keshav Naik、Sreeji Nair、Venkata P. Palle、Sunanda Dastidar、Abhijit Ray、M.S. Alam、Mohammad Salman、Ian A. Cliffe、Viswajanani Sattigeri

  DOI：10.1016/j.bmcl.2010.07.069

  日期：2010.9

  A novel set of compounds with a 1,3-dioxolane ring which acts as a proline bioisostere have been successfully designed as VLA-4 receptor antagonists. Compounds (18e), (28j), and (35g) were shown to have high receptor affinities. (C) 2010 Elsevier Ltd. All rights reserved.